Plain-English translation of NCT07401199 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The PRISM-GC study is developing an artificial intelligence tool to predict how well advanced stomach cancer will respond to neoadjuvant chemotherapy combined with PD-1 inhibitor immunotherapy. Researchers will analyze your CT scans and tissue samples using advanced computer learning to create a prediction model. If successful, this tool could help doctors personalize treatment plans in the future, ensuring each patient receives the most effective therapy.
Currently, doctors cannot reliably predict which patients with advanced stomach cancer will benefit most from chemotherapy and immunotherapy before surgery, even though responses vary significantly. This study aims to fill that gap by creating an artificial intelligence system that could guide treatment decisions and help avoid unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
As a participant, you will receive your standard neoadjuvant chemotherapy combined with immunotherapy as planned by your doctor—this is not an experimental treatment. You will have your routine CT scans and pathology samples collected before treatment begins, and researchers will analyze these images and tissue using artificial intelligence. You will also donate blood and tissue samples for genetic analysis. The study is observational, meaning researchers are collecting and analyzing your medical information to build the prediction tool, not testing a new intervention on you.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China